GELITA Launches Ultra-Low Endotoxin MEDELLAPRO Gelatin for Sensitive Biomedical Applications
核心洞察
GELITA has launched MEDELLAPRO (搜索) Ultra Low Endotoxin gelatin, featuring fewer than ten endotoxin units per gram, to support advanced biomedical product development.
The new excipient expands GELITA's Endotoxin Controlled Excipients portfolio, targeting applications such as surgical sealants, hemostatic agents, scaffolds, and drug delivery systems.
GELITA states these products could enable breakthroughs in drug delivery, vaccine stabilisation, tissue engineering, 3D bioprinting, and regenerative medicine.
GELITA, a specialist in collagen and gelatin technologies, has expanded its offering with the launch of MEDELLAPRO (搜索) Ultra Low Endotoxin gelatin, which the company reports features less than ten endotoxin units per gram. The new excipient is designed to enable the development of advanced, sensitive biomedical products, ranging from surgical sealants and hemostatic agents to scaffolds and drug delivery systems.
The launch broadens GELITA's Endotoxin Controlled Excipients (ECE) portfolio, a line of excipients engineered to ensure maximum safety, biocompatibility, and regulatory compliance. GELITA said in its statement that these products could pave the way for "breakthroughs in drug delivery, vaccine stabilisation, tissue engineering, 3D bioprinting and regenerative medicine," providing researchers and manufacturers with reliable, high-purity ingredients.
Expanding the Endotoxin Controlled Excipients Portfolio
The MEDELLAPRO (搜索) launch represents a strategic extension of GELITA's ECE portfolio, which is tailored to meet the stringent requirements of emerging biomedical fields. The company will showcase its latest advancements in excipient technology at BIO International 2026 in San Diego (Booth 3335-DF), featuring two flagship products from the ECE portfolio:
- MEDELLAPRO (gelatin) — the newly launched ultra-low endotoxin gelatin.
- VACCIPRO (collagen peptides) — trusted for stabilising vaccines and injectables, offering low allergenic potential, high tolerability, and protection for sensitive molecules.
Advancing Recombinant Collagen Proteins
Beyond its gelatin and collagen peptide offerings, GELITA is advancing biotechnological processes to develop animal-free, recombinant collagen proteins. The company states these will offer resource-efficient and sustainable solutions for the future.
As part of the conference programme, GELITA will host a scientific lecture titled "The Role of Non-Animal Recombinant Collagen Proteins in Biomedical Applications: From Vaccine Stabilization to Artificial Organs." The presentation will be delivered by Dr Michelle Montgomery, Senior Manager, R&D, GELITA, on Tuesday, June 23, 2026, at 2:45 PM, in Theatre 4.
Visitors to BIO International 2026 are invited to visit GELITA at Booth 3335-DF in the German Pavilion to explore how MEDELLAPRO (搜索) and VACCIPRO (搜索) are shaping the future of vaccine development, medical devices, and biomedical innovation.